Bipolar
Dream :
|
| Home | |
| About Us | |
| About Elves | |
| Mission Statement | |
| What Is Support? | |
| Support Groups | |
| Expert Column | |
| Future | |
| Volunteering | |
| Contact Us | |
Antipsychotic Drugs as Antidepressantsby Prof. Gordon Parker |
|
![]() |
Prof. Gordon Parker is the Director of the Black Dog Institute, a Prince of Wales Hospital-based facility which seeks to improve the clinical assessment and management of mood disorders, as well as undertake innovative research, and run educational and training programs. He is a Scientia Professor at the University of New South Wales, respecting his international research reputation. He was previously the Head of the School of Psychiatry and Director of Psychiatry at Prince of Wales and Prince Henry Hospitals, and part-time Director of Research at Woodbridge Hospital, Singapore. He has written a number of books on mood disorders and has been the author of over 400 scientific publications. |
Antipsychotic drugs were developed to primarily treat delusions and hallucinations but comparative analyses of the ‘old’ antipsychotic drugs with the ‘old ‘antidepressants showed many years ago that the antipsychotic drugs were equally effective and, when they worked, that they often worked rapidly and faster than antidepressants. This could have argued for their wider use as antidepressant drugs per se. However, their take up as antidepressants did not occur to any great degree, presumably because clinicians were concerned about side-effects, and tardive dyskinesia in particular. The ‘new’ antipsychotic drugs (often called the ‘atypical antipsychotics’) appear to have similar or even slightly superior efficacy compared to the older antipsychotic drugs and fewer side-effects, with the risk of tardive dyskinesia being distinctly less. In the last few years we have noticed that the addition of an atypical
antipsychotic to an antidepressant drug may be associated with a marked
improvement. In essence, while I would still prescribe a single antidepressant
by itself, if the depressed individual had not improved with that drug
and with a somewhat broader second antidepressant trialled, I would then
often add an atypical antipsychotic in a number of instances, particularly
when the patient has a more ‘biological’ depression. I sometimes note
rapid improvement with a low-dose of the atypical antipsychotic when
added to the antidepressant, and generally tend to cease the atypical
within a week after recovery. In some other situations, the individual
may need a higher dose of the atypical and for an extended period, as
withdrawing it may cause relapse. The extended use of an atypical psychotic
together with an antidepressant is not an orthodox strategy and over
the next few years we should anticipate guidelines for the use of atypical
antipsychotics to be developed and considered carefully in the management
of depression. |
|